Posted by Michael Wonder on 10 May 2021
China NMPA approves PARP inhibitor pamiparib for patients with previously treated advanced ovarian cancer
7 May 2021 - This marks the first approval of pamiparib and the third BeiGene discovered medicine to receive regulatory approval.
BeiGene today announced that its PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration for the treatment of patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.
The new drug application was previously granted priority review by the Center for Drug Evaluation in July 2020. BeiGene is preparing to launch pamiparib this month.
